ARDT
Ardent Health, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
10.99
▲ 0.51 (4.87%)
MARKET · —
Price
Open
10.17
Prev close
10.48
Day high
11.02
Day low
10.35
Volume
175.76K
Market cap
$1.55B
P/E (TTM)
19.98
52W range
7.71 – 15.48
Trailing performance
Returnvs SPY
1W
+0.73%
+2.1%
1M
+5.47%
+1.7%
3M
+19.33%
+16.2%
6M
+16.79%
+5.7%
YTD
+24.46%
+12.2%
1Y
-15.59%
-35.6%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.55B
Enterprise value$3.48B
Revenue (TTM)$6.41B
Gross profit$3.74B
EBITDA$422.42M
Net income$78.23M
EPS (TTM)$0.55
Free cash flow$208.31M
Total cash$724.48M
Total debt$2.27B
Book value / share$9.52
Shares outstanding141.05M
Float52.10M
Short % of float13.57%
Dividend yield—
Beta (5Y)0.70
Valuation & profitability ratios
Trailing P/E19.98
Forward P/E8.95
PEG ratio—
Price / sales—
Price / book1.15
EV / revenue0.54
EV / EBITDA8.25
Gross margin58.38%
Operating margin3.44%
Profit margin1.22%
Return on equity9.96%
Return on assets3.13%
Debt / equity130.19
Current ratio2.11
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total revenue | $6.32B | $5.97B | $5.41B |
| Cost of revenue | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 |
| R&D | — | — | — |
| SG&A | — | — | — |
| Operating income | — | — | — |
| Pre-tax income | — | — | — |
| Tax provision | $0 | $0 | $0 |
| Net income | $135.81M | $210.34M | $53.90M |
| EBIT | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash & equivalents | — | — | — |
| Short-term investments | — | — | — |
| Net receivables | — | — | — |
| Inventory | — | — | — |
| Total current assets | — | — | — |
| Total assets | — | — | — |
| Total current liabilities | — | — | — |
| Long-term debt | — | — | — |
| Total liabilities | — | — | — |
| Retained earnings | — | — | — |
| Shareholder equity | — | — | — |
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net income | $135.81M | $210.34M | $53.90M |
| Depreciation | — | — | — |
| Change in working capital | — | — | — |
| Operating cash flow | — | — | — |
| Capital expenditure | — | — | — |
| Investing cash flow | — | — | — |
| Dividends paid | — | — | — |
| Buybacks | — | — | — |
| Financing cash flow | — | — | — |
| Net change in cash | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.19 | 0.27 | +44.0% |
| Mar 2026 | 0.18 | 0.30 | +68.2% |
| Dec 2025 | 0.35 | 0.36 | +4.5% |
| Sep 2025 | 0.42 | 0.83 | +95.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.25 | 5 | $1.60B | +1.7% |
| Next quarter | 0.34 | 5 | $1.63B | +1.7% |
| Current year | 1.09 | 4 | $6.46B | +2.2% |
| Next year | 1.23 | 5 | $6.73B | +4.1% |
Analyst targets & ownership
Mean target$12.68
High target$14.00
Low target$10.00
Implied upside15.39%
Analyst count11
ConsensusBUY
Strong buy / Buy1 / 6
Hold4
Sell / Strong sell0 / 1
Held by insiders23.84%
Held by institutions76.74%
Institutions holding188
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
33.62M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 1, 26 | CASPERS DAVE Chief Executive Officer |
STOCK | 103.65K | $0 | Direct |
| Jun 5, 26 | LUMSDAINE ALFRED Chief Financial Officer |
BUY | 10.00K | $88.10K | Direct |
| Jun 5, 26 | DEMICHIEI ROBERT Director |
BUY | 11.26K | $98.30K | Direct |
| Apr 1, 26 | BYNOE PETER C B Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | GOODYEAR WILLIAM M Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | HAVDALA ELLEN Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | BONICK MARTIN Chief Executive Officer |
STOCK | 134.62K | $0 | Direct |
| Apr 1, 26 | LUMSDAINE ALFRED Chief Financial Officer |
STOCK | 53.85K | $0 | Direct |
| Apr 1, 26 | BULGARELLI PETER J Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | DEMICHIEI ROBERT Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | WEBB ROBERT THOMAS Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | CASPERS DAVE Chief Operating Officer |
STOCK | 35.67K | $0 | Direct |
| Apr 1, 26 | ROBINSON EDMONDO Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | SOTIR MARK R Chairman of the Board |
STOCK | 14.23K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BONICK MARTIN |
Chief Executive Officer | 1.44M | Stock Award(Grant) |
BYERS DAVID RAYNOR |
Officer | 130.44K | Stock Award(Grant) |
BYNOE PETER C B |
Director | 115.37K | Stock Award(Grant) |
CASPERS DAVE |
Chief Executive Officer | 174.93K | Stock Award(Grant) |
CHERNIN ETHAN |
Officer | 68.40K | Stock Award(Grant) |
GOODYEAR WILLIAM M |
Director | 115.37K | Stock Award(Grant) |
HAVDALA ELLEN |
Director | 115.37K | Stock Award(Grant) |
LUMSDAINE ALFRED |
Chief Financial Officer | 329.18K | Purchase |
PETROVICH STEPHEN C |
General Counsel | 1.15M | Stock Award(Grant) |
WEBB ROBERT THOMAS |
Director | 78.22K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
10.90
+0.85% from price
SMA 20
10.98
+0.13% from price
SMA 50
10.34
+6.30% from price
SMA 100
9.91
+10.88% from price
SMA 200
9.61
+14.38% from price
EMA 12
10.87
+1.10% from price
EMA 26
10.75
+2.21% from price
EMA 50
10.46
+5.09% from price
RSI (14)
54.7
Neutral
MACD (12,26,9)
0.12
Hist -0.08
ATR (14)
0.49
4.42% of price
Realised vol 30D
38.4%
Annualised
Bollinger upper
11.55
20, 2σ
Bollinger lower
10.40
20, 2σ
50 / 200 cross
Golden
10.34 vs 9.61
Trend bias
Above 200
+14.38%
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
38.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-48.5%
Peak to trough
Max drawdown 5Y
-61.2%
Peak to trough
ATR 14
0.49
4.42% of price
Beta (reported)
0.70
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
12.50
+13.7% from spot
ATM implied vol
60.5%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
8
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
12.50
100 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Implied Volatility Surging for Ardent Health Stock Options
Zacks · 9d ago
Ardent Health (ARDT) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
Oklahoma Heart Institute Brings New National Cardiovascular Trials and Technologies to Patients Across the Region
Business Wire · 11d ago
Is Ardent Health (ARDT) Cheap On Lowered Guidance And Weaker Q2 Earnings?
Simply Wall St. · 15d ago
New Strong Sell Stocks for August 7th
Zacks · 16d ago
Ardent Health Inc (ARDT) (Q2 2026) Earnings Call Highlights: Raising Impact Program Savings ...
GuruFocus.com · 17d ago
Ardent Health Q2 Earnings Call Highlights
MarketBeat · 17d ago
Ardent Health Partners, LLC Q2 2026 Earnings Call Summary
Moby · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.